Create a free research account to view current pricing and place an order.
How does VIP work in research models?
VIP is a vasoactive intestinal peptide acting through VPAC receptors with roles in vasodilation, bronchodilation, immune modulation, gut signaling, and neuroendocrine regulation.
What is the half-life of VIP?
Half-life: Short acting.
Human pharmacokinetics are not standardized. Treat exposure as short acting unless compound-specific data or formal formulation labeling indicates otherwise.
Research dosing reference
100-500 mcg daily or protocol-specific exposure depending on route and tolerance.
Dose interpretation (U-100 units)
| Target dose | U-100 units |
|---|---|
| 100 mcg | 2 units |
| 250 mcg | 5 units |
| 500 mcg | 10 units |
Units are concentration-specific - confirm against your actual reconstitution volume.
How is VIP reconstituted?
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 10 mg | 2 mL BAC Water | 0.050 mg/unit |
Injection timing
Often used earlier in day or protocol-specific windows; monitor hemodynamic response.
Beginner escalation
Begin low due to vasodilatory and immune-modulatory effects.
Side-effect mitigation
Monitor flushing, blood pressure changes, headache, dizziness, GI effects, or immune response shifts.
Stack compatibility
Use caution with blood-pressure-active or immune-modulatory agents.
Storage & stability
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically.
Protocol duration & reassessment
Short protocol blocks with blood-pressure and symptom reassessment are preferred before extension or repeat course.
Frequently asked questions
What is VIP and how is it studied?
VIP is a vasoactive intestinal peptide acting through VPAC receptors with roles in vasodilation, bronchodilation, immune modulation, gut signaling, and neuroendocrine regulation. VIP is catalogued in the Hormonal / Miscellaneous group of this reference and is studied in laboratory and in-vitro models only.
What is known about the half-life of VIP?
Reference half-life for VIP: short acting. Human pharmacokinetics are not standardized. Treat exposure as short acting unless compound-specific data or formal formulation labeling indicates otherwise. Published pharmacokinetic figures come from research and clinical-literature contexts and are listed here as reference values for laboratory work only, not as guidance for any person or animal.
How is VIP stored?
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically. Lyophilized research peptides are generally kept cold, dry, and away from light, and reconstituted solutions are labeled with concentration and date. Follow the storage conditions documented for the specific lot you receive.
How is VIP reconstituted for laboratory work?
The reference reconstitution for the 10 mg vial is 2 mL BAC Water, which gives a concentration of about 5 mg/mL. Concentration equals peptide mass divided by diluent volume, so adding more liquid lowers the concentration. Add diluent slowly down the vial wall, swirl rather than shake, and confirm the arithmetic before preparing any research solution.
Is VIP FDA approved?
No. The research-grade VIP described here is an investigational, research-use-only material and is not an FDA-approved drug product. Where an approved pharmaceutical form of a compound exists, it is a separate prescription product. This reference is not medical advice, and the material is not for human or animal consumption.
VIP product overview · VIP cost · All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration